Copyright Reports & Markets. All rights reserved.

Global Nanostructured Drug Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Nanostructured Drug Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Nanostructured Drug Market Size Growth Rate by Product
      • 1.4.2 Liposomes
      • 1.4.3 Polymeric Micelles
      • 1.4.4 Solid lipid Nanoparticles
      • 1.4.5 Microemulsion and Nanoemulsion
      • 1.4.6 Nanosuspension
    • 1.5 Market by End User
      • 1.5.1 Global Nanostructured Drug Market Size Growth Rate by End User
      • 1.5.2 Cancer and Tumors
      • 1.5.3 Autoimmune Disorders
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Nanostructured Drug Market Size
      • 2.1.1 Global Nanostructured Drug Revenue 2014-2025
      • 2.1.2 Global Nanostructured Drug Sales 2014-2025
    • 2.2 Nanostructured Drug Growth Rate by Regions
      • 2.2.1 Global Nanostructured Drug Sales by Regions
      • 2.2.2 Global Nanostructured Drug Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Nanostructured Drug Sales by Manufacturers
      • 3.1.1 Nanostructured Drug Sales by Manufacturers
      • 3.1.2 Nanostructured Drug Sales Market Share by Manufacturers
      • 3.1.3 Global Nanostructured Drug Market Concentration Ratio (CR5 and HHI)
    • 3.2 Nanostructured Drug Revenue by Manufacturers
      • 3.2.1 Nanostructured Drug Revenue by Manufacturers (2014-2019)
      • 3.2.2 Nanostructured Drug Revenue Share by Manufacturers (2014-2019)
    • 3.3 Nanostructured Drug Price by Manufacturers
    • 3.4 Nanostructured Drug Manufacturing Base Distribution, Product Types
      • 3.4.1 Nanostructured Drug Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Nanostructured Drug Product Type
      • 3.4.3 Date of International Manufacturers Enter into Nanostructured Drug Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Nanostructured Drug Sales by Product
    • 4.2 Global Nanostructured Drug Revenue by Product
    • 4.3 Nanostructured Drug Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Nanostructured Drug Breakdown Data by End User

    6 North America

    • 6.1 North America Nanostructured Drug by Countries
      • 6.1.1 North America Nanostructured Drug Sales by Countries
      • 6.1.2 North America Nanostructured Drug Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Nanostructured Drug by Product
    • 6.3 North America Nanostructured Drug by End User

    7 Europe

    • 7.1 Europe Nanostructured Drug by Countries
      • 7.1.1 Europe Nanostructured Drug Sales by Countries
      • 7.1.2 Europe Nanostructured Drug Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Nanostructured Drug by Product
    • 7.3 Europe Nanostructured Drug by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Nanostructured Drug by Countries
      • 8.1.1 Asia Pacific Nanostructured Drug Sales by Countries
      • 8.1.2 Asia Pacific Nanostructured Drug Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Nanostructured Drug by Product
    • 8.3 Asia Pacific Nanostructured Drug by End User

    9 Central & South America

    • 9.1 Central & South America Nanostructured Drug by Countries
      • 9.1.1 Central & South America Nanostructured Drug Sales by Countries
      • 9.1.2 Central & South America Nanostructured Drug Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Nanostructured Drug by Product
    • 9.3 Central & South America Nanostructured Drug by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Nanostructured Drug by Countries
      • 10.1.1 Middle East and Africa Nanostructured Drug Sales by Countries
      • 10.1.2 Middle East and Africa Nanostructured Drug Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Nanostructured Drug by Product
    • 10.3 Middle East and Africa Nanostructured Drug by End User

    11 Company Profiles

    • 11.1 Merck
      • 11.1.1 Merck Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Merck Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Merck Nanostructured Drug Products Offered
      • 11.1.5 Merck Recent Development
    • 11.2 Pfizer
      • 11.2.1 Pfizer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Pfizer Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Pfizer Nanostructured Drug Products Offered
      • 11.2.5 Pfizer Recent Development
    • 11.3 Novartis
      • 11.3.1 Novartis Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 Novartis Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 Novartis Nanostructured Drug Products Offered
      • 11.3.5 Novartis Recent Development
    • 11.4 Abbott
      • 11.4.1 Abbott Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Abbott Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Abbott Nanostructured Drug Products Offered
      • 11.4.5 Abbott Recent Development
    • 11.5 GlaxoSmithKline
      • 11.5.1 GlaxoSmithKline Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 GlaxoSmithKline Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 GlaxoSmithKline Nanostructured Drug Products Offered
      • 11.5.5 GlaxoSmithKline Recent Development
    • 11.6 Roche
      • 11.6.1 Roche Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Roche Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Roche Nanostructured Drug Products Offered
      • 11.6.5 Roche Recent Development
    • 11.7 Sanofi
      • 11.7.1 Sanofi Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Sanofi Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Sanofi Nanostructured Drug Products Offered
      • 11.7.5 Sanofi Recent Development
    • 11.8 Eli Lilly
      • 11.8.1 Eli Lilly Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 Eli Lilly Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 Eli Lilly Nanostructured Drug Products Offered
      • 11.8.5 Eli Lilly Recent Development
    • 11.9 Astrazeneca
      • 11.9.1 Astrazeneca Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Astrazeneca Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Astrazeneca Nanostructured Drug Products Offered
      • 11.9.5 Astrazeneca Recent Development
    • 11.10 Johnson & Johnson
      • 11.10.1 Johnson & Johnson Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Johnson & Johnson Nanostructured Drug Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Johnson & Johnson Nanostructured Drug Products Offered
      • 11.10.5 Johnson & Johnson Recent Development
    • 11.11 Celgene
    • 11.12 Novavax
    • 11.13 Stryker
    • 11.14 Gilead Sciences
    • 11.15 OSI Pharmaceuticals
    • 11.16 Kadmon Pharmaceuticals
    • 11.17 Samyang Biopharm
    • 11.18 Mitsubishi Pharma
    • 11.19 Kaken Pharmaceutical
    • 11.20 Selecta Biosciences
    • 11.21 Par Pharmaceutical
    • 11.22 Cerulean Pharma
    • 11.23 Navidea Biopharmaceuticals
    • 11.24 Lummy

    12 Future Forecast

    • 12.1 Nanostructured Drug Market Forecast by Regions
      • 12.1.1 Global Nanostructured Drug Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Nanostructured Drug Revenue Forecast by Regions 2019-2025
    • 12.2 Nanostructured Drug Market Forecast by Product
      • 12.2.1 Global Nanostructured Drug Sales Forecast by Product 2019-2025
      • 12.2.2 Global Nanostructured Drug Revenue Forecast by Product 2019-2025
    • 12.3 Nanostructured Drug Market Forecast by End User
    • 12.4 North America Nanostructured Drug Forecast
    • 12.5 Europe Nanostructured Drug Forecast
    • 12.6 Asia Pacific Nanostructured Drug Forecast
    • 12.7 Central & South America Nanostructured Drug Forecast
    • 12.8 Middle East and Africa Nanostructured Drug Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Nanostructured Drug Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global Nanostructured Drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Nanostructured Drug market based on company, product type, end user and key regions.

      This report studies the global market size of Nanostructured Drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Nanostructured Drug in these regions.
      This research report categorizes the global Nanostructured Drug market by top players/brands, region, type and end user. This report also studies the global Nanostructured Drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Merck
      Pfizer
      Novartis
      Abbott
      GlaxoSmithKline
      Roche
      Sanofi
      Eli Lilly
      Astrazeneca
      Johnson & Johnson
      Celgene
      Novavax
      Stryker
      Gilead Sciences
      OSI Pharmaceuticals
      Kadmon Pharmaceuticals
      Samyang Biopharm
      Mitsubishi Pharma 
      Kaken Pharmaceutical
      Selecta Biosciences
      Par Pharmaceutical
      Cerulean Pharma
      Navidea Biopharmaceuticals
      Lummy

      Market size by Product
      Liposomes
      Polymeric Micelles
      Solid lipid Nanoparticles
      Microemulsion and Nanoemulsion
      Nanosuspension
      Market size by End User
      Cancer and Tumors
      Autoimmune Disorders

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Nanostructured Drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Nanostructured Drug market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Nanostructured Drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Nanostructured Drug submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Nanostructured Drug are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Nanostructured Drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now